Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ZD-6126 AstraZeneca.

Jens Soltau1, Joachim Drevs

  • 1Tumor Biology Center, Department of Medical Oncology, Breisacher Strasse 117, 79106 Freiburg, Germany. drevs@tumorbio.uni-freiburg.de

Idrugs : the Investigational Drugs Journal
|April 2, 2004
PubMed
Summary

AstraZeneca is developing ZD-6126, a novel vascular-targeting agent, for potential cancer treatment. This tubulin-binding compound shows promise in targeting tumor blood vessels.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Second-line therapy adjustment for advanced pancreatic cancer using circulating tumor cells: Preliminary results.

Cancer treatment and research communications·2025
Same author

Adjusting Treatment Strategies Using Circulating Tumor Cells: Preliminary Results on Metastatic Colorectal Cancer.

Anticancer research·2025
Same author

Treatment of advanced solid tumours with NSAIDs: Correlation of quantitative monitoring of circulating tumour cells and positron emission tomography-computed tomography imaging.

Oncology letters·2016
Same author

First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2014
Same author

Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors.

International journal of clinical pharmacology and therapeutics·2011
Same author

Biomarkers in tumor angiogenesis and anti-angiogenic therapy.

International journal of molecular sciences·2011

Area of Science:

  • Oncology
  • Pharmacology
  • Vascular Biology

Background:

  • Cancer treatment remains a significant challenge.
  • Vascular-targeting agents offer a novel therapeutic strategy.
  • Tubulin-binding compounds interfere with cell division.

Purpose of the Study:

  • To introduce ZD-6126, a new vascular-targeting agent.
  • To highlight its mechanism as a tubulin-binding agent.
  • To discuss its potential in cancer therapy.

Main Methods:

  • Development of ZD-6126 by AstraZeneca.
  • Licensing agreement with Angiogene Pharmaceuticals Ltd.
  • Characterization of ANG-400 series agents.

Main Results:

  • ZD-6126 is identified as a promising candidate.
  • It belongs to the ANG-400 series of vascular-targeting agents.
  • Its tubulin-binding properties are noted.

Conclusions:

  • ZD-6126 demonstrates potential for cancer treatment.
  • Further development is underway by AstraZeneca.
  • The agent targets tumor vasculature.

Related Experiment Videos